Abstract:Glioblastoma multiforme (GBM) patients have a high recurrence rate of 90%, and the 5-year survival rate is only about 5%. Cytosine deaminase (CDA)/5-fluorocytosine (5-FC) gene therapy is a promising glioma treatment as 5-FC can cross the blood-brain barrier (BBB), while 5-fluorouracil (5-FU) cannot. Furthermore, 5-FU can assist reversing the immunological status of cold solid tumors. This study developed mesenchymal stem cells (MSCs) co-expressing yeast CDA and the secretory IL18-FC superkine to prevent recurrent tumor progression by simultaneously exerting cytotoxic effects and enhancing immune responses. IL18 was fused with Igk and IgG2a FC domains to enhance its secretion and serum half-life. The study confirmed the expression and activity of the CDA enzyme, as well as the expression, secretion, and activity of secretory IL18 and IL18-FC superkine, which were expressed by lentiviruses transduced-MSCs. In the transwell tumor-tropism assay, it was observed that the genetically modified MSCs retained their selective tumor-tropism ability following transduction. CDA-expressing MSCs, in the presence of 5-FC (200 µg/ml), induced cell cycle arrest and apoptosis in glioma cells through bystander effects in an indirect transwell co-culture system. They reduced the viability of the direct co-culture system when they constituted only 12.5 % of the cell population. The effectiveness of engineered MSCs in suppressing tumor progression was assessed by intracerebral administration of a lethal dose of GL261 cells combined in a ratio of 1:1 with MSCs expressing CDA, or CDA and sIL18, or CDA and sIL18-FC, into C57BL/6 mice. PET scan showed no conspicuous tumor mass in the MSC-CDA-sIL18-FC group that received 5-FC treatment. The pathological analysis showed that tumor progression suppressed in this group until 20th day after cell inoculation. Cytokine assessment showed that both interferon-gamma (IFN-γ) and interleukin-4 (IL-4) increased in the serum of MSC-CDA-sIL18 and MSC-CDA-sIL18-FC, treated with normal saline (NS) compared to those of the control group. The MSC-CDA-sIL18-FC group that received 5-FC treatment showed reduced serum levels of IL-6 and a considerably improved survival rate compared to the control group. Therefore, MSCs co-expressing yeast CDA and secretory IL18-FC, with tumor tropism capability, may serve as a supplementary approach to standard GBM treatment to effectively inhibit tumor progression and prevent recurrence.

Bone Marrow-Derived Mesenchymal Stem Cells Co-Expressing Interleukin-18 and Interferon-Β Exhibit Potent Antitumor Effect Against Intracranial Glioma in Rats.

Migration and localization of bone marrow mesenchymal stem cells labeled by DAPI in the brain of glioma rat models

Interleukin-18- and HSV-tk-expressing Bone Marrow Stromal Cells Exhibit Antiglioma Activity

Adenoviral‐mediated Interleukin‐18 Expression in Mesenchymal Stem Cells Effectively Suppresses the Growth of Glioma in Rats

Peritumoral administration of IFN upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model

Gene therapy of rat intracranial glioma by Mesenchymal Stem Cells (MSCs) transfected with the beta-interferon gene

Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model

bone marrow derived mesenchymal stem cells mediated dual gene therapy for glioblastoma

The potential of mesenchymal stem cell coexpressing cytosine deaminase and secretory IL18-FC chimeric cytokine in suppressing glioblastoma recurrence

Mesenchymal Stem Cells As Therapeutic Agents and in Gene Delivery for the Treatment of Glioma

Experimental Study of Treatment ofIntracranial G422 Glioblastoma with Bone Marrow-derived Dendritic Cells Vaccine

Antitumor Effects Of Interleukin-18 Gene-Modified Hepatocyte Cell Line On Implanted Liver Carcinoma

Human Menstrual Blood-Derived Mesenchymal Stem Cells As a Cellular Vehicle for Malignant Glioma Gene Therapy

Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells Co-Expressing IFN-γ and IL-10 Inhibit Hepatocellular Carcinoma by Modulating MAPK Pathway.

Investigation on the Inhibition Effects of Bone Marrow Mesenchymal Stem Cells with CD Gene on Glioma in C6 Rat*

Interferon-Beta Gene-Modified Human Bone Marrow Mesenchymal Stem Cells Attenuate Hepatocellular Carcinoma Through Inhibiting Akt/Foxo3a Pathway

Antitumor effect of IL-12 gene-modified bone marrow mesenchymal stem cells combined with Fuzheng Yiliu decoction in an in vivo glioma nude mouse model

Bone Marrow Mesenchymal Stem Cells (BMSC) Exosome-Derived mR-512-5p Inhibits the Proliferation and Apoptosis of Glioblastoma Cells

Interferon- β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway

Study of MiR-451 in the Treatment of Human Gliomas through Regulating the AMPK Pathway Mediated by Bone Mesenchymal Stem Cells

A Tumor-Selective Biotherapy with Prolonged Impact on Established Metastases Based on Cytokine Gene-Engineered MSCs.